Product Images Gabapentin

This is a medication labeled as Gavmpentin with a unique identification code NDCH 73630-00K-45. It appears to have been manufactured by a company named "B Totratied oo gupesci B A." The medication is available at all drug outlets. The additional alphanumeric codes are likely batch and lot numbers, with the expiration date of 12/2024. The GTIN code is also included for tracking and inventory purposes.*

The text provides a chart (Figure 1) of a clinical study evaluating the effectiveness of Gabapentin in reducing pain scores. The study was conducted over an 8-week period, which included a 4-week dose titration period followed by a 4-week fixed dose period. The chart shows the weekly mean pain scores for the observed cases, including a baseline measurement. The study compared the pain scores for those taking Gabapentin at a dose of 3,600 mg/day with those on a placebo.*

This is a chart depicting the Mean Pain Score over a 7-week period divided into a 3-week Dose Titration Period and a 4-week Fixed Dose Period. The study had three groups: a placebo group, a Gabapentin 1,800 mg/day group, and a Gabapentin 2,400 mg/day group. The figure shows the weekly mean pain scores for the ITT population observed cases in Study 2.*

This is a figure that represents the proportion of responders in controlled studies on Postherpetic Neuralgia (PHN), which is a pain condition caused by nerve damage from shingles. The graph shows the percentage of patients who had greater than 50% reduction in their pain score at the endpoint of the study. The results are separated into two groups: one that received placebo (PBO) and the other that received gabapentin (GBP), a medication commonly used to treat neuropathic pain. The graph shows that the proportion of responders is higher in the GBP group compared to the PBO group. There are also statistical significance markers (*, ***) indicating the p-value for the results at different levels of confidence.*

This is a formula used to estimate renal function in adults based on their age, weight, and serum creatinine levels. The formula is different for female patients, where the product is multiplied by 0.85.*